Custom Antibody Market: Growth, Size, Share, and Trends

Custom Antibody Market Size, Share & Trends

The global custom antibody market in terms of revenue was estimated to be worth $579 million in 2024 and is poised to reach $901 million by 2029, growing at a CAGR of 9.2% from 2024 to 2029. The market's growth is mainly driven by government funding and support for research in antibody-related fields, coupled with the expansion into translational medicine. Custom antibodies are integral to personalized therapies, as they can be designed to target specific molecular markers unique to an individual patient's disease. The growing emphasis on personalized medicine drives demand for custom antibody solutions.

Custom Antibody Market Trends

To know about the assumptions considered for the study, Request for Free Sample Report

Attractive Opportunities in the Custom Antibody Market

Global Custom Antibody Market Dynamics

DRIVER: Growing importance of custom antibody in precision medicine

Precision medicine assures better health by accounting for individual variations in genes, environment, and lifestyle. Precision medicine will impact healthcare in the coming decade as it expands to key areas such as artificial intelligence, routine clinical genomics, environment, and returning value across a diverse population. Through the precision medicine approach, each patient's treatment can be focused on drugs most likely individually beneficial, thus relieving the patient from additional costs and potentially harmful side effects of other drugs that may not be as effective. The growing use of precision medicine in diseases like cancer fuels the demand for custom antibodies, which can be used in targeted therapy to treat various tumors. Monoclonal antibodies (mAbs) are the latest drugs that fit the precision medicine paradigm. According to a personalized medicine coalition report in 2023, more than 38% of FDA approvals accounted for precision medicines for each of the last seven years. Precision medicine is a broader platform for researchers to determine specific medical challenges for diseases and treatment. Thus, the number of precision medicines for treatments and diagnosis has increased significantly and is expected to continue to rise in the coming years. This is likely to support the growth of the market in the coming years.

RESTRAINT: High-cost and time-consuming antibody development from transgenic animals

The high cost and time-intensive nature of custom antibody production, particularly when utilizing transgenic animals, serve as significant restraining factors for the growth of the market. Developing antibodies through transgenic animals involves complex procedures and considerations, adding to the overall timeline and costs associated with the process. For instance, the preparation of recombinant antibodies from antigen preparation to protein purification from cDNA can be less costly compared to monoclonal or polyclonal antibody development. However, the production of monoclonal antibodies (mAbs) using transgenic animals requires substantial capital investments, spanning from antigen preparation to mAb purification using techniques like affinity chromatography. This reliance on animals for hybridoma production further increases costs and adds logistical complexities to the process.

OPPORTUNITY: High scope for growth in emerging economies

The expanding healthcare markets in the Asia Pacific and Latin American regions present significant growth opportunities for players in the market. These regions are witnessing a rise in infectious and chronic diseases, coupled with increasing research and development initiatives focusing on innovative proteomics and genomics techniques. The emphasis on proteomics research, particularly in countries like China, Brazil, and India, underscores the demand for custom antibodies to support antibody-based proteomics studies. Moreover, the establishment of organizations like the Proteomics Society, India (PSI) facilitates research collaborations and workshops on proteomics, further driving the demand for custom antibodies. The vast population bases in countries like China, India, Brazil, and Mexico offer sustainable markets for immunotherapy drugs, fueled by lifestyle changes and the increasing prevalence of chronic diseases. Additionally, the rising research and development expenditure in Asia, expected to surpass 50% of the global total by 2030, highlights the high growth potential in emerging markets.

CHALLENGE: Challenges associated with safety and stability

In the market, several challenges are associated with ensuring the safety and stability of antibodies. One major challenge is employing transgenic animals to create antibodies, which entails significant costs and time investments. However, transgenic cattle have been proposed for high production of bispecific single-chain variable fragments (scFv). The common challenges arise from the need for expensive production platforms and stringent control over cell growth conditions to maintain viability and prevent the release of byproducts during manufacturing. Variations in culture conditions can lead to significant variations in post-translational modifications (PTMs) and functional activity of final products, necessitating detailed understanding and strict control over process parameters. This becomes particularly challenging during the implementation of processes into new laboratories and during scaling up operations.

Global Custom Antibody Industry Ecosystem Analysis

The custom antibody market ecosystem comprises raw material suppliers, service providers, regulatory authorities, and end users, such as academic & research institutes, pharmaceutical & biotechnology companies, and contract research organizations.

The antibody characterization segment held a dominant share in the antibody development segment in the custom antibody industry.

Based on the service, the custom antibody market has been segmented into antibody development, antibody production & purification, and antibody fragmentation & labeling. The antibody development is further sub-segmented into antigen preparation, immunization & hybridoma production, and antibody characterization. In 2023, antibody characterization accounted for the largest share of the antibody development market. This is attributed to the advances in characterization technologies, such as mass spectrometry, flow cytometry, and surface plasmon resonance, which have enhanced the ability to analyze antibodies in detail. These technologies enable more precise and comprehensive characterization, driving the segment's growth.

The therapeutic application segment is expected to register the fastest growth of the custom antibody industry during the forecast period.

Based on the application, the custom antibody market has been segmented into research and therapeutics. In 2023, the research application segment accounted for the largest market share, and is therapeutics segment expected to achieve the highest CAGR during the projected period. The key drivers of research in the market include the substantial investment in oncology research and development by pharmaceutical and biotechnology companies drives innovation and the creation of new custom antibodies.

North America accounted for the largest share of the custom antibody industry in 2023

Geographically, the custom antibody market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America held the dominant share, followed by Europe. North America has been a leader in supporting research to develop targeted drug therapies. Thus, the growing number of clinical trials in the region is contributing to the growth of the North American market.

To know about the assumptions considered for the study, download the pdf brochure

Key players in the global custom antibody market include Thermo Fisher Scientific Inc. (US), GenScript (US), Bio-Rad Laboratories, Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc (US), Revvity, Inc. (US), Bio-Techne (US), ROCKLAND IMMUNOCHEMICALS, INC. (US), Laboratory Corporation of America Holdings (US), Inotiv (US), Danaher Corporation (US), Sino Biological, Inc. (China), KANEKA CORPORATION (Japan), OriGene Technologies, Inc. (US), Absolute Biotech (US), Biointron Biologics (China), Cell Signaling Technology, Inc. (US), Curia Global, Inc. (US), Mabtech (Sweden), ACROBiosystems (US), Elabscience Bionovation Inc. (US), Creative Diagnostics (US), CUSABIO TECHNOLOGY LLC (US), BioGenes GmbH (Germany), RayBiotech, Inc. (US), Proteintech Group, Inc (US), IMGENEX INDIA Pvt Ltd. (India), Synbio Technologies (US), ProSci Incorporated (US), Creative Biolabs (US).

Scope of the Custom Antibody Industry:

This report categorizes the custom antibody market to forecast revenue and analyze trends in each of the following submarkets:

By Service

• Antibody Development
  • Antigen Preparation
  • Immunization & Hybridoma Production
  • Antibody Characterization
• Antibody Production & Purification
• Antibody Fragmentation & Labeling

By Type

• Monoclonal Antibodies
• Polyclonal Antibodies
• Recombinant Antibodies
• Others

By Source

• Mice
• Rabbits
• Others

By Application

• Research
• Therapeutics

By Indication

• Oncology
• Infectious Disease
• Immunology
• Neurobiology
• Cardiovascular Diseases
• Other Indications

By End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific (APAC)
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLATAM)
• Middle East & Africa
  • Middle East
    • GCC Countries
      • Saudi Arabia (KSA)
      • United Arab Emirates (UAE)
      • Rest of GCC Countries
    • Rest of Middle East (RoME)
  • Africa

Recent Developments of the Custom Antibody Industry:

• In December 2022, Merck KGaA collaborated with Kelun-Biotech to develop seven investigational preclinical antibody-drug conjugates (ADC) for cancer treatment.
• In November 2022, GenScript collaborated with Applied Cells Inc. to deliver combined cell isolation solutions worldwide for cell therapy drug development.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst